Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.53 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 3/20 | 0.44 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.44 |
| ▸ | NPY1R | P25929 | 1/20 | 0.44 |
| ▸ | NPY2R | P49146 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10442914 | 0.86 | MEN1 (0.48) | KMT2AMEN1TSHRNPSR1KDM4E | |
| SCHEMBL24491489 | 0.85 | KMT2A (0.53) | KMT2AMEN1TSHRNPSR1KDM4E | |
| SCHEMBL24319645 | 0.84 | KMT2A (0.56) | KMT2AMEN1TSHRNPSR1KDM4E | |
| SCHEMBL17285638 | 0.84 | KMT2A (0.56) | KMT2AMEN1TSHRNPSR1KDM4E | |
| SCHEMBL24319647 | 0.84 | KMT2A (0.56) | KMT2AMEN1TSHRNPSR1KDM4E | |
| SCHEMBL2800684 | 0.83 | KMT2A (0.48) | KMT2AMEN1TSHRKDM4ELMNA | |
| SCHEMBL11668191 | 0.83 | — | — | |
| SCHEMBL23155886 | 0.80 | MAPT (0.59) | KMT2AMEN1TSHRNPSR1KDM4E | |
| SCHEMBL13014522 | 0.80 | MAPT (0.59) | KMT2AMEN1TSHRNPSR1KDM4E | |
| SCHEMBL19710826 | 0.79 | KMT2A (0.62) | KMT2AMEN1TSHRKDM4EUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9994515-B2 | Aryl naphthyl methanone oxime(s) and process for preparation thereof | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2018-06-12 | — | — | US | disclosed |
| US-20160304442-A1 | ARYL NAPHTHYL METHANONE OXIME(S) AND PROCESS FOR PREPARATION THEREOF | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304442-A1 | ARYL NAPHTHYL METHANONE OXIME(S) AND PROCESS FOR PREPARATION THEREOF | MCL1, CYP11B1, CYP21A2 | KMT2A 786/4885MEN1 197/4885TSHR 3103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.